• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

The EYES Have It: Research Reveals 3 Stocks to Buy

Want an antidote for volatility? Do your homework.
By JIM COLLINS
Sep 10, 2015 | 04:00 PM EDT
Stocks quotes in this article: ACU, EYES, SUND, BRK.A, BRK.B

When I worked as an equity research analyst at DLJ in the 1990s, one of my fellow analysts would say, "When the market is falling, an analyst should be doing more research." Very wise advice.

When everything is going up, up, up, it's easy to be an expert on every stock one owns. Even if one never does any research at all.

What could go wrong? The Fed's got my back! Well, the markets haven't been drinking that Kool-Aid for the past five weeks, so it's time to put shoes on the pavement.

So on Wednesday -- at an investment conference and over the phone -- I talked to a passel of CEOs. Those conversations reassured me on a couple of current positions and convinced me to start a new one.

A few highlights:

Acme United (ACU). I met with CEO Walter Johnsen yesterday in New York. While I have always sung the praises of ACU's defensive product offer -- scissors, knives, pencil sharpeners, first-aid kits, etc. -- it occurred to me in speaking with Johnsen that ACU is in perfect position to play offense. Why?

ACU is a prime beneficiary of the devaluation of the Chinese yuan. The majority of ACU's products are made in China, they sell very little there, and ACU's principal raw materials -- the company is the world's largest manufacturer of scissors -- are plastic and steel, prices for which have fallen based on concerns about, you guessed it, China.

With the ACU board's recent declaration of a $0.09 per share regular quarterly dividend for shareholders of record Oct. 1, it's time to buy Acme United and ride out this market volatility.

Second Sight Medical Products (EYES). I spoke with EYES' Chairman Bob Greenberg and newly named CEO Will McGuire at some length at that same conference in NYC yesterday.

Investors seem to have forgotten about EYES' revolutionary Argus II bionic eye in the midst of the recent market turmoil.

McGuire's mandate is clearly to ramp up near-term sales of Argus II. The product works, and EYES recently published a study of three years' worth of data from its first Argus II patient cohort.

Broadening Argus II's indication from retinitis pigmentosa to age-related macular degeneration (AMD) is a key growth driver for EYES. The first implant of Argus II in an AMD patient went quite well, and Greenberg noted yesterday that the implanting hospital, the Manchester Royal Eye Center, had been deluged with calls from AMD sufferers wishing to participate in the implantation study.

So Second Sight's no flash in the pan, but to get EYES stock back to its first-trading-day levels, the company is going to have to increase its pace of implantation from the 19 to 20 that were done in the first and second quarters.

McGuire is clearly focused on increasing the penetration of Argus II, and I still believe in EYES' story and the company's ability to produce sight restoration that is nothing short of miraculous.

Sundance Strategies (SUND). I spoke with Sundance CEO Kraig Higginson yesterday. Sundance participates in the market for Life Settlements, a transaction in which a third party purchases a life insurance policy from the policyholder and then pays premiums and ultimately receives death benefits after the former policyholder dies.

Insurance industry heavyweights like Warren Buffett's Berkshire Hathaway (BRK.A, BRK.B) and Apollo are involved in the Life Settlements game, and it's clearly a niche business that requires much due diligence.

Sundance management goes through individual policies in incredible detail and uses an outside consultant to check their work. Then, unlike many of the other Life Settlements players, it actually has its own policies de-risked by using a re-insurer.

So, it's a bulletproof system, and Higginson noted that he was most proud of seeing the system progress through an entire loop. The process has been confirmed, and SUND is in the process of a bond issuance, which will monetize current policies and would free up the company to buy more policies.

Life Settlements work, and SUND's capital structure gives it a level of safety that is most attractive in these wild markets.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Collins was long ACU, EYES and SUND, although positions may change at any time.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

2 Health-Related Stocks See Bits of Insider Interest

Bret Jensen
Apr 19, 2021 10:00 AM EDT

Large purchases of Cortexyme Inc. and NantHealth Inc. shares have been made by insiders recently.

UnitedHealth Group's Charts Look Strong

Bruce Kamich
Apr 16, 2021 11:35 AM EDT

Here's where traders should look to buy a pullback.

Cigna Has Made a Huge Upside Breakout

Bruce Kamich
Apr 16, 2021 10:55 AM EDT

Traders could go long CI at current levels, and we have two price objectives.

Jim Cramer: We've Got a Boom ... and a Bust

Jim Cramer
Apr 15, 2021 3:36 PM EDT

Let's look at this impossible move on the market -- and why health care could be coming off life support.

TransMedics Group's Charts Are Pointed Lower

Bruce Kamich
Apr 15, 2021 9:30 AM EDT

These charts are not pretty.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:05 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How recency bias and the Pareto Principle impact y...
  • 02:42 PM EDT PAUL PRICE

    Wednesday on Real Money Pro

    Make this stock a 'part' of your portfolio.
  • 04:44 PM EDT PAUL PRICE

    Pretty Incredible + Hard to Believe

  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login